China-led team replicates human embryo ‘invasion’ of the womb for the first time

Scientists create a ‘mini-womb’ 3D model on a microfluidic chip which could lead to treatments for women affected by ...
AOL

Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?

On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
Seeking Alpha

CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using ...

BRISBANE, Calif. and EDEN PRAIRIE, Minn., April 05, 2023 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA) and Miromatrix Medical Inc. (MIRO) -- today announced an exclusive partnership aimed at advancing the ...
Business Wire

Trestle Bio Announces Research Collaboration with Humacyte

SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing ...
Seeking Alpha

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of ...

– Positive preclinical results of the small-diameter ATEV were recently presented at The American Heart Association’s Scientific Sessions 2024 meeting – DURHAM, N.C., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ...
Nasdaq

Humacyte, Inc. Announces FDA Approval for SYMVESS as First-in-Class Bioengineered Vascular ...

Humacyte, Inc. has announced that the FDA has granted full approval for SYMVESS, a novel bioengineered human tissue designed for use as a vascular conduit in patients with extremity arterial injuries ...
Nasdaq

United Therapeutics and Intermountain Health Announce the First Patient Treated With ...

A phase 1 study of miroliverELAP for the treatment of acute liver failure is currently underway;1 first patient in the study underwent the procedure at Intermountain Medical Center in Murray, Utah ...